Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC

Ejemplares similares

• Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR
  por: Gilbert, Jill, et al.
  Publicado: (2015)
• Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
  por: Yang, Hui, et al.
  Publicado: (2018)
• Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle
  por: Ferris, Robert L, et al.
  Publicado: (2015)
• Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status
  por: Rizvi, Naiyer, et al.
  Publicado: (2015)
• A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors
  por: Papadopoulos, Kyriakos P, et al.
  Publicado: (2015)